Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + clarithromycin + metronidazole + tinidazole + levofloxacin + furazolidone + tetracycline (Shandong University)
- Development stage
- Unknown
- Lead developer
- Shandong University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination refers to a pool of seven antimicrobial agents—amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone, and tetracycline—evaluated by Shandong University for the treatment of *Helicobacter pylori* infection. In the context of a Phase 4 clinical trial, these antibiotics are used as part of an antimicrobial susceptibility testing (AST)-guided salvage therapy. Patients receive a 14-day bismuth-based quadruple regimen consisting of a proton pump inhibitor (PPI), colloidal bismuth pectin, and two antibiotics selected from this pool based on their susceptibility profiles. The individual components work through various mechanisms, including inhibition of bacterial cell wall synthesis (amoxicillin), protein synthesis (clarithromycin, tetracycline), and DNA replication or integrity (metronidazole, tinidazole, levofloxacin, furazolidone), collectively aimed at eradicating resistant *H. pylori* strains.
- Other names
- AST-Guided Salvage H. Pylori Treatment antibioticsBismuth-based quadruple therapy antibiotics
02
Targets
Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)Bacterial RibosomeTopo IV (Bacterial Topoisomerase IV)NTR (Bacterial nitroreductase)DNA gyraseDNA
Beyond the preview
Go deeper on amoxicillin + clarithromycin + metronidazole + tinidazole + levofloxacin + furazolidone + tetracycline (Shandong University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + clarithromycin + metronidazole + tinidazole + levofloxacin + furazolidone + tetracycline (Shandong University).